ACAD Stock Forecast & Price Target

Acadia Pharmaceuticals is supported by a durable commercial base in NUPLAZID and DAYBUE, both of which hold first-and-only positions in their approved indications and anchor cash-generating franchises in neurology and rare disease. The broader pipeline also supports a positive outlook, as remlifanserin showed efficacy signals in Alzheimer’s disease psychosis despite narrowly missing the primary endpoint, with nominal secondary endpoint significance and meaningful post hoc results in a subgroup of roughly 80% of patients with higher baseline severity. Importantly, its safety profile appeared improved versus pimavanserin, with no QT prolongation signal and low discontinuation rates of 2.4% for 60 mg and 2.6% for placebo, which strengthens confidence in the Phase 3 program and long-term pipeline value.

Acadia Pharmaceuticals is facing a negative outlook because its ACP-204 Phase 2 data in Alzheimer's disease psychosis narrowly missed the primary SAPS-H+D endpoint, with the 60 mg dose showing only a 2.2-point placebo-adjusted benefit and a borderline p-value of 0.0603, while the 30 mg dose failed outright. The weak signal appears especially concerning given the 42% placebo response, which consumed most of the observed improvement and leaves uncertainty around Phase 3 powering, enrichment, and timelines, despite clean safety. More broadly, the company remains exposed to high CNS development failure risk, competitive pressure from larger biotech and pharma players, and reliance on NUPLAZID and DAYBUE to sustain commercialization.